Cargando…

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Tape, Christopher J., Ling, Stephanie, Dimitriadi, Maria, McMahon, Kelly M., Worboys, Jonathan D., Leong, Hui Sun, Norrie, Ida C., Miller, Crispin J., Poulogiannis, George, Lauffenburger, Douglas A., Jørgensen, Claus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cell Press 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628167/ https://www.ncbi.nlm.nih.gov/pubmed/27315484 http://dx.doi.org/10.1016/j.cell.2016.05.079

Ejemplares similares

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
por: Tape, Christopher J., et al.
Publicado: (2016)

Reproducible Automated Phosphopeptide Enrichment Using Magnetic TiO(2) and Ti-IMAC
por: Tape, Christopher J., et al.
Publicado: (2014)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014)

Oncogenic KRAS: Signaling and Drug Resistance
por: Kim, Hyeon Jin, et al.
Publicado: (2021)

Immune modulatory effects of oncogenic KRAS in cancer
por: Hamarsheh, Shaima’a, et al.
Publicado: (2020)

Targeting the undruggable oncogenic KRAS: the dawn of hope
por: Asimgil, Hande, et al.
Publicado: (2022)

Conquering oncogenic KRAS and its bypass mechanisms
por: Hou, Pingping, et al.
Publicado: (2022)

Proteomics profiling of interactome dynamics by colocalisation analysis (COLA)
por: Mardakheh, Faraz K., et al.
Publicado: (2017)

Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
por: Sabnis, Amit J, et al.
Publicado: (2009)

Oncogenic KRAS promotes malignant brain tumors in zebrafish
por: Ju, Bensheng, et al.
Publicado: (2015)

Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
por: Collins, Meredith A., et al.
Publicado: (2012)

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
por: Liu, Xinquan, et al.
Publicado: (2019)

Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
por: Luo, Yongde, et al.
Publicado: (2021)

Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer
por: Kamerkar, Sushrut, et al.
Publicado: (2017)

KRAS insertion mutations are oncogenic and exhibit distinct functional properties
por: White, Yasmine, et al.
Publicado: (2016)

Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
por: Wang, Dali, et al.
Publicado: (2022)

The Loss of ATRX Increases Susceptibility to Pancreatic Injury and Oncogenic KRAS in Female But Not Male Mice
por: Young, Claire C., et al.
Publicado: (2018)

Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy
por: Wang, Stephanie J., et al.
Publicado: (2020)

RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer
por: Kang, R, et al.
Publicado: (2014)

Kras as a key oncogene and therapeutic target in pancreatic cancer
por: Collins, Meredith A., et al.
Publicado: (2014)

The proto-oncogene KRAS is targeted by miR-200c
por: Kopp, Florian, et al.
Publicado: (2013)

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype
por: Fu, Yong, et al.
Publicado: (2015)

Oncogenic Kras drives invasion and maintains metastases in colorectal cancer
por: Boutin, Adam T., et al.
Publicado: (2017)

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
por: Tang, Daolin, et al.
Publicado: (2021)

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
por: Zhu, Gongmin, et al.
Publicado: (2021)

Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
por: Sunaga, Noriaki, et al.
Publicado: (2021)

Past and Future Strategies to Inhibit Membrane Localization of the KRAS Oncogene
por: Haidar, Malak, et al.
Publicado: (2021)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
por: Salmón, Marina, et al.
Publicado: (2023)

CRISPR prime editing for unconstrained correction of oncogenic KRAS variants
por: Jang, Gayoung, et al.
Publicado: (2023)

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
por: Kim, Dongsung, et al.
Publicado: (2023)

Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
por: Learte-Aymamí, Soraya, et al.
Publicado: (2022)

Targeted Degradation of Oncogenic KRAS(G12C) by VHL-Recruiting PROTACs
por: Bond, Michael J., et al.
Publicado: (2020)

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
por: Sánchez-Muñoz, Alfonso, et al.
Publicado: (2010)

Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS
por: Stelniec-Klotz, Iwona, et al.
Publicado: (2012)

Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
por: Santana-Codina, Naiara, et al.
Publicado: (2018)

Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function
por: Kattan, Walaa E, et al.
Publicado: (2019)

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
por: Kempf, Emmanuelle, et al.
Publicado: (2016)

A reciprocal role of prostate cancer on stromal DNA damage
por: Banerjee, Jheelam, et al.
Publicado: (2013)

Systematic evaluation of quantotypic peptides for targeted analysis of the human kinome
por: Worboys, Jonathan D., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ik5fusbrk2ltcp8rf93gcmkj6b